Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
03/01/2021 03/02/2021 03/03/2021 03/04/2021 03/05/2021 Date
206.47(c) 204.14(c) 202(c) 200.54(c) 206.92(c) Last
2 797 548 3 445 286 3 660 317 4 308 430 3 805 681 Volume
+0.77% -1.13% -1.05% -0.72% +3.18% Change
More quotes
Financials (USD)
Sales 2021 27 838 M - -
Net income 2021 7 091 M - -
Net Debt 2021 9 688 M - -
P/E ratio 2021 26,6x
Yield 2021 1,64%
Sales 2022 28 067 M - -
Net income 2022 7 583 M - -
Net Debt 2022 6 771 M - -
P/E ratio 2022 24,4x
Yield 2022 1,80%
Capitalization 188 B 188 B -
EV / Sales 2021 7,10x
EV / Sales 2022 6,94x
Nbr of Employees 35 000
Free-Float 99,6%
More Financials
Company
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products... 
Sector
Pharmaceuticals
Calendar
03/09 | 09:45amPresentation
More about the company
Notations Surperformance© of Eli Lilly and Company
Trading Rating : Investor Rating :
More Ratings
All news about ELI LILLY AND COMPANY
03/05ELI LILLY AND  : AbCellera's Covid-19 Treatment Gets Recommendation From Europea..
DJ
03/05ABCELLERA BIOLOGICS  : Eli Lilly Land European Medicines Agency's Positive Opini..
MT
03/05EU regulator advises on use of Lilly's COVID-19 antibody cocktail
RE
03/05ELI LILLY AND  : Gets CHMP Positive Opinion for Covid-19 Treatments
DJ
03/05ELI LILLY AND  : Receives EU Health Regulator's Positive Opinion On Bamlanivimab..
MT
03/05EU regulator advises on use of Lilly's COVID-19 antibody cocktail
RE
03/05ELI LILLY AND COMPANY  : - Tirzepatide achieved superior A1C and body weight red..
AQ
03/04ELI LILLY AND COMPANY  : - Baricitinib is First JAK-Inhibitor to Demonstrate Hai..
AQ
03/03Starboard Takes Elanco Stake, Nominates Three to Its Board -- Update
DJ
03/03ELI LILLY AND  : Incyte Say Baricitinib Meets Phase 3 Efficacy Endpoint in Treat..
MT
03/03INCYTE, ELI LILLY  : Baricitinib Meets Main Endpoint in Alopecia Areata Study
DJ
03/03ELI LILLY AND  : Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth..
PR
03/01ELI LILLY AND COMPANY  : - Lilly announces additional doses of neutralizing anti..
AQ
02/26ELI LILLY AND  : US Government to Purchase 100,000 Doses of Eli Lilly's Bamlaniv..
MT
02/26GLOBAL MARKETS LIVE: Aibnb, Salesforce, AT&T
More news
News in other languages on ELI LILLY AND COMPANY
03/04CORONAVIRUS : homologation de traitement en France jugée prématurée
02/26Les Taux mettent le feu à la Tech
02/26EN DIRECT DES MARCHES  : Engie, Saint-Gobain, Teleperformance, Danone, Lagardère..
02/16BASILEA PHARMACEUTICA  : GlobeNewswire/Basilea meldet für 2020 starke -2-
02/10MÄRKTE USA/Neuen Rekorden folgen kleine Gewinnmitnahmen
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 210,65 $
Last Close Price 206,92 $
Spread / Highest target 23,7%
Spread / Average Target 1,80%
Spread / Lowest Target -42,0%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY22.55%187 971
JOHNSON & JOHNSON-0.81%410 337
ROCHE HOLDING AG-1.63%274 753
PFIZER INC.-7.09%191 873
ABBVIE INC.-0.42%188 420
NOVARTIS AG-6.52%186 338